Yanagisawa Ryu, Nakazawa Yozo, Sakashita Kazuo, Tanaka Miyuki, Shikama Naoto, Kamijo Takehiko, Shiohara Masaaki, Koike Kenichi
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Pediatr Transplant. 2009 Sep;13(6):737-45. doi: 10.1111/j.1399-3046.2008.01065.x. Epub 2008 Dec 16.
We here report the efficacy and toxicity of a conditioning regimen with fractionated 8-Gy TBI, fludarabine, and cyclophosphamide in allogeneic HSCT for pediatric hematological malignancies. Among 22 children who received related or unrelated HSCT, nine were transplanted with refractory disease and/or from HLA two or more loci-mismatched family donors. None of the patients developed graft failure. The Seattle grading system revealed that 18 patients had no RRT, and the remaining patients had grade I gastrointestinal toxicity alone. The estimated overall survival and leukemia-free survival at two yr were 57.1% and 48.0%, respectively, in 10 patients with acute lymphoblastic leukemia; 91.7% and 71.3%, respectively, in 12 patients with myeloid leukemia. The incidence of TRM was 4.8% at two yr. The rates of RRT above grade II and TRM in an 8-Gy TBI-containing regimen were significantly lower than the data of historical control patients who underwent 12-Gy TBI and cyclophosphamide with or without etoposide. The intermediate-dose TBI-based conditioning regimen may confer successful engraftment combined with minimized RRT, although its efficacy should be further evaluated.
我们在此报告在儿科血液系统恶性肿瘤的异基因造血干细胞移植中,采用分次8 Gy全身照射、氟达拉滨和环磷酰胺的预处理方案的疗效和毒性。在22例接受相关或无关造血干细胞移植的儿童中,9例移植时患有难治性疾病和/或来自HLA两个或更多位点不匹配的家族供者。所有患者均未发生移植物失败。西雅图分级系统显示,18例患者无重度放射性损伤,其余患者仅出现I级胃肠道毒性。10例急性淋巴细胞白血病患者2年时的估计总生存率和无白血病生存率分别为57.1%和48.0%;12例髓系白血病患者分别为91.7%和71.3%。2年时移植相关死亡率为4.8%。含8 Gy全身照射方案中II级以上重度放射性损伤和移植相关死亡率显著低于接受12 Gy全身照射和环磷酰胺(含或不含依托泊苷)的历史对照患者的数据。基于中等剂量全身照射的预处理方案可能实现成功植入,同时使重度放射性损伤最小化,尽管其疗效仍需进一步评估。